Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2020 Jun 10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Cardioangiologica 2020 Jun 10

DOI: 10.23736/S0026-4725.20.05222-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Knowledge and attitudes towards hypertriglyceridaemia and associated residual risk amongst cardiologists in Turkey

Öner ÖZDOĞAN 1, Özcan BAŞARAN 2 , Barış GÜNGÖR 3, Ümit Y. SINAN 4, Meral KAYIKÇIOĞLU 5

1 Department of Cardiology, Tepecik Education and Research Hospital, Tepecik, Turchia; 2 Department of Cardiology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turchia; 3 Department of Cardiology, Siyami Ersek Education and Research Hospital, Siyami Ersek, Turchia; 4 Department of Cardiology, Cardiology Institute, Istanbul University Cerrahpasa, Cerrahpasa, Istanbul; 5 Department of Cardiology, Faculty of Medicine, Ege University, Bornova, İzmir, Turchia


PDF


BACKGROUND: Hypertriglyceridaemia (HTG) is an important component of residual risk. The knowledge regarding its treatment might not be at a desired level, which might prevent patients from receiving the maximum benefit. We aimed to investigate the knowledge and attitudes of Turkish cardiologists who responded to a survey regarding HTG treatment.
METHODS: A multiple-choice survey was conducted to analyse Turkish cardiologists’ management of HTG. The questionnaire was submitted by the Turkish Society of Cardiology to all its members.
RESULTS: A total of 160 cardiologists responded to the survey. The mean age was 37.5 ± 8.5 years, and 35 (21.9%) of the participants were female. Most of the participants (88%) thought HTG was a risk factor, and 75% of them felt confident in diagnosing and treating HTG. Patient compliance (41%), polypharmacy (33%), and lack of treatment options (15%) were the most common problems obstructing treatment of HTG. A proportion of 96% of the participants knew about non-high-density lipoprotein cholesterol, which is a good surrogate marker of atherogenic dyslipidaemia; however, only 39% were using it as a treatment goal. In the case of low-density lipoprotein cholesterol at goal but with HTG (residual risk), the first choice for treatment was fibrates (94%). Half of cardiologists had never used omega-3 fatty acids as a treatment option.
CONCLUSIONS: Although most of the participating cardiologists felt competent treating HTG, there was a knowledge gap in the treatment of atherogenic dyslipidaemia and management of residual risk. Evidence of the benefit of lowering triglycerides from cardiovascular outcome trials is eagerly awaited. There is also an unmet need of increasing patient compliance and managing polypharmacy.


KEY WORDS: Hypertriglyceridaemia; Residual risk; Polypharmacy; Cardiologist

inizio pagina